
Brian Newell is Deputy Vice President of Public Affairs at PhRMA and serves as lead spokesperson for national media. Before joining PhRMA in 2020, he served as managing director of strategic communications for the Biotechnology Innovation Organization (BIO). Prior to BIO, Brian worked on Capitol Hill for ten years, including roles on the Education and Workforce Committee, the House Republican Conference and the Ways and Means Committee. Brian graduated with a BA in Political Science from the University of Maine, his home state. He enjoys spending time with his wife and two children – especially summer vacations on the lake in Maine.
Recent Posts
What is missing in the current drug pricing plan

A recent congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important...
Read More
What is Kaiser Family Foundation up to?

For years, Kaiser Family Foundation (Kaiser) has reminded lawmakers that Americans are opposed to government “negotiation” in drug pricing should it lead to less access to medicines and destroy...
Read More
Industry leaders discuss the impact of the drug pricing debate

This month, PhRMA hosted a media briefing with leaders within the biopharmaceutical industry to discuss the dangers of current proposals on government price setting, while also sharing alternative...
Read More
New reports shed light on key facts about medicines and affordability

A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers...
Read More
The latest misleading “poll” on drug pricing

When a front group for insurers and drug cost middlemen promote a poll on drug pricing, everyone’s immediate reaction should include a healthy dose of skepticism. The same is true for a poll from the...
Read More
New insulin report highlights how incentives benefit middlemen, harm patients

The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More